198 related articles for article (PubMed ID: 28000737)
1. Development of an in-vivo active reversible butyrylcholinesterase inhibitor.
Košak U; Brus B; Knez D; Šink R; Žakelj S; Trontelj J; Pišlar A; Šlenc J; Gobec M; Živin M; Tratnjek L; Perše M; Sałat K; Podkowa A; Filipek B; Nachon F; Brazzolotto X; Więckowska A; Malawska B; Stojan J; Raščan IM; Kos J; Coquelle N; Colletier JP; Gobec S
Sci Rep; 2016 Dec; 6():39495. PubMed ID: 28000737
[TBL] [Abstract][Full Text] [Related]
2. The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.
Košak U; Brus B; Knez D; Žakelj S; Trontelj J; Pišlar A; Šink R; Jukič M; Živin M; Podkowa A; Nachon F; Brazzolotto X; Stojan J; Kos J; Coquelle N; Sałat K; Colletier JP; Gobec S
J Med Chem; 2018 Jan; 61(1):119-139. PubMed ID: 29227101
[TBL] [Abstract][Full Text] [Related]
3. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.
Greig NH; Utsuki T; Ingram DK; Wang Y; Pepeu G; Scali C; Yu QS; Mamczarz J; Holloway HW; Giordano T; Chen D; Furukawa K; Sambamurti K; Brossi A; Lahiri DK
Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17213-8. PubMed ID: 16275899
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
5. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors.
Karlsson D; Fallarero A; Brunhofer G; Mayer C; Prakash O; Mohan CG; Vuorela P; Erker T
Eur J Pharm Sci; 2012 Aug; 47(1):190-205. PubMed ID: 22683890
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
7. Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT
Więckowska A; Kołaczkowski M; Bucki A; Godyń J; Marcinkowska M; Więckowski K; Zaręba P; Siwek A; Kazek G; Głuch-Lutwin M; Mierzejewski P; Bienkowski P; Sienkiewicz-Jarosz H; Knez D; Wichur T; Gobec S; Malawska B
Eur J Med Chem; 2016 Nov; 124():63-81. PubMed ID: 27560283
[TBL] [Abstract][Full Text] [Related]
8. N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
Košak U; Knez D; Coquelle N; Brus B; Pišlar A; Nachon F; Brazzolotto X; Kos J; Colletier JP; Gobec S
Bioorg Med Chem; 2017 Jan; 25(2):633-645. PubMed ID: 27908752
[TBL] [Abstract][Full Text] [Related]
9. Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
Bono GF; Simão-Silva DP; Batistela MS; Josviak ND; Dias PF; Nascimento GA; Souza RL; Piovezan MR; Souza RK; Furtado-Alle L
Neurochem Int; 2015 Feb; 81():57-62. PubMed ID: 25624079
[TBL] [Abstract][Full Text] [Related]
10. Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes.
Pajk S; Knez D; Košak U; Zorović M; Brazzolotto X; Coquelle N; Nachon F; Colletier JP; Živin M; Stojan J; Gobec S
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):498-505. PubMed ID: 31914836
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Sang Z; Pan W; Wang K; Ma Q; Yu L; Yang Y; Bai P; Leng C; Xu Q; Li X; Tan Z; Liu W
Eur J Med Chem; 2017 Apr; 130():379-392. PubMed ID: 28279845
[TBL] [Abstract][Full Text] [Related]
12. Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease.
Bartolini M; Greig NH; Yu QS; Andrisano V
J Chromatogr A; 2009 Mar; 1216(13):2730-8. PubMed ID: 18950780
[TBL] [Abstract][Full Text] [Related]
13. Butyrylcholinesterase-Activated Near-Infrared Fluorogenic Probe for In Vivo Theranostics of Alzheimer's Disease.
Wang L; Sun T; Zhen T; Li W; Yang H; Wang S; Feng F; Chen Y; Sun H
J Med Chem; 2024 Apr; 67(8):6793-6809. PubMed ID: 38546542
[TBL] [Abstract][Full Text] [Related]
14. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
15. Multiple Ligands Targeting Cholinesterases and β-Amyloid: Synthesis, Biological Evaluation of Heterodimeric Compounds with Benzylamine Pharmacophore.
Szałaj N; Bajda M; Dudek K; Brus B; Gobec S; Malawska B
Arch Pharm (Weinheim); 2015 Aug; 348(8):556-63. PubMed ID: 26032855
[TBL] [Abstract][Full Text] [Related]
16. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
17. Syntheses, cholinesterases inhibition, and molecular docking studies of pyrido[2,3-b]pyrazine derivatives.
Hameed A; Zehra ST; Shah SJ; Khan KM; Alharthy RD; Furtmann N; Bajorath J; Tahir MN; Iqbal J
Chem Biol Drug Des; 2015 Nov; 86(5):1115-20. PubMed ID: 25951978
[TBL] [Abstract][Full Text] [Related]
18. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor.
Brus B; Košak U; Turk S; Pišlar A; Coquelle N; Kos J; Stojan J; Colletier JP; Gobec S
J Med Chem; 2014 Oct; 57(19):8167-79. PubMed ID: 25226236
[TBL] [Abstract][Full Text] [Related]
19. Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine.
Darvesh S; McDonald RS; Darvesh KV; Mataija D; Conrad S; Gomez G; Walsh R; Martin E
Bioorg Med Chem; 2007 Oct; 15(19):6367-78. PubMed ID: 17681768
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo.
Więckowska A; Więckowski K; Bajda M; Brus B; Sałat K; Czerwińska P; Gobec S; Filipek B; Malawska B
Bioorg Med Chem; 2015 May; 23(10):2445-57. PubMed ID: 25868744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
